Listen to the conference from yesterday at how FAST the whole DDex program is moving along. While i give the generics about a ZERO chance of winning the patent case now before Avnr imagine this. that product is going to be WORTHLESS anyway when Ddex is out. No ones going to use it. We'll be off producing Nuedexta ...the sequel....with a patent life of perhaps until 2035....22 YeARS from now...and they would have won....nothing..for all their efforts except a product they'd be lucky to sell 10 scripts for. Assuming the CEO's of the generic companies bought those 10 themselves that is.
what we have here is really quite incredible. Scripts growing at 5% here in the U.S for PBA alone...the EU approval now WEEKS away...a likely BIG partnership to follow....DDEX, the sequel coming ....all the other uses for this drug.
for the next 22 years.
folks.....LOOK at the stock price now. Because it's not going to last long at this level.
This is a stock destined to trade MUCH higher in the next few years.
there is not going to be a short basher left standing when this is all said and done.
I think this is more of Trade's fantasy-talk.
When the time comes, I do not think deut-dex-5 mg quin will compete well with the much cheaper generic dex/10 mg quin.
The added safety of 5 mg of quin versus 10 mg of quin. will not be much of a selling point compared to what will largely be a big difference in price.